Nugenerex Immuno-OncologyNUGX
13F holders, Q1 2026 (March 31)2holders +1
1new positions
0sold out
$0.00avg. 13F price*
At the end of Q1 2026, 2 institutions reported holding Nugenerex Immuno-Oncology Inc. (NUGX) in their 13F filings, up 1 from Q2 2025. 1 opened new positions and 0 sold out. The largest holders were NBT Bank, N.A. ($0) and Ballast Advisors LLC ($0).
- Company
- Nugenerex Immuno-Oncology Inc.
- CUSIP
- 67053X102
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q1 2026: 48 shares bought, net +48 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| NBT Bank, N.A. | 0.00% | Add +0.0% | 42 | $0 |
| Ballast Advisors LLC | 0.00% | New | 6 | $0 |
"% of holder's portfolio" is NUGX's weight in each manager's 13F, not the share of Nugenerex Immuno-Oncology Inc. the manager owns.